Exane BNP Paribas initiated coverage of Idexx Laboratories with an Outperform rating and $602 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDXX:
- Idexx Laboratories upgraded to Buy from Neutral at Cleveland Research
- Early notable gainers among liquid option names on December 4th
- Idexx Laboratories narrows FY23 EPS view to $9.74-$9.90 from $9.64-$9.90
- Idexx Laboratories reports Q3 EPS $2.53 with items, consensus $2.37
- Idexx Laboratories price target lowered to $460 from $500 at Stifel